Bioconjugations in immunotherapy

Immunotherapy represents a burgeoning array of strategies aimed at harnessing the power of the immune system to combat various disease states. In one of our projects, we employ the tools of bioorthogonal chemistry to tailor the surfaces of immune cells, including NK cells, with diverse targeting moieties. These engineered immune cells exhibit enhanced efficacy in eradicating cancer cells compared to their unmodified counterparts. Our current focus involves exploring the potential of this chemically engineered cells in cancer immunotherapy as a viable alternative to genetically modified CAR T cells. In another project, we plan to develop new conjugation methods to modify antibodies.